COMMUNIQUÉS West-GlobeNewswire

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026
Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than 30% as Pluri advances its longevity and U.S. [...]
Cannara Announces a Long-Term International Cannabis Supply Agreement with Curaleaf International Limited
14/07/2026
MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Smile Doctors Outpaces First-Half Growth Plan, Nears 600 Locations Nationwide
14/07/2026
Entering its second decade, the nation's largest ortho-focused support organization posts double-digit first-half growth as new orthodontist affiliations, de novo expansion and accelerating adult demand continue to [...]
ASPN 2026 to Feature Three Abstracts on SPRINT® PNS
14/07/2026
- 12-Month Outcomes from the RESET™ Trial for Low Back Pain Recognized as Top Abstract Award winner - CLEVELAND, July 14, 2026 (GLOBE NEWSWIRE) -- Pain medicine physicians from across the U.S. will continue to expand [...]
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
14/07/2026
EMJX Shifted from “Stress” to “Mixed” for Bitcoin Company Files Updated Investor Presentation Outlining Performance and Strategy Management to Host Fireside Chat Today at 10:30am ET NORTH PALM BEACH, Fla., July 14, 2026 [...]
Cannara annonce la conclusion d’une entente internationale à long terme d’approvisionnement en cannabis avec Curaleaf International Limited
14/07/2026
MONTRÉAL, 14 juill. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous ») ( TSX: LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de qualité [...]
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
14/07/2026
Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minneapolis, MN, July 14 [...]
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
14/07/2026
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase 2b [...]
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
14/07/2026
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, [...]
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
14/07/2026
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII deficiency (FVIID) [...]
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
14/07/2026
BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that Signal Transduction and Targeted Therapy (STTT), a Nature Portfolio journal, published a paper titled " [...]
XOMA Royalty Announces Closing of Its Acquisition by Ligand
14/07/2026
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. [...]
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
14/07/2026
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension [...]
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. [...]
Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards
14/07/2026
From 647 applications worldwide, Hummingbird Bioscience was selected by an independent judging panel as a winner at the AI Discovery Awards hosted by Nebius The awards program spotlights companies leveraging AI to [...]
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
14/07/2026
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion [...]
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07/2026
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and [...]
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07/2026
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is [...]
Transactions in connection with share buy-back program
14/07/2026
Company announcement no. 25 - 26 14 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]

Pages